Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic.

◾ Patient baseline characteristics were taken from the relevant CANA trial in that setting. Treatment effects also came from these trials, with the exception of the comparison to SITA in triple therapy and with DAPA as an add-on to insulin, where treatment effects were taken from the results of a network meta-analysis (NMA; Pacou et al22 and data on file) since direct comparisons were not available (Table 1)